Guide contents
Open in calculatorCompound briefing
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide first isolated from rabbit cerebral venous blood during induced sleep. Across decades of research it has been studied for slow-wave sleep promotion, circadian regulation, stress-axis modulation and analgesic effects, with a notably benign tolerability profile.
The research question
DSIP research concerns sleep architecture rather than simple sedation. EEG measures, stress-axis activity and next-day function are more informative endpoints than sleep onset alone.
Mechanism & research themes
Exact receptor target remains uncharacterised. Demonstrated effects include modulation of the HPA axis (reduced ACTH/cortisol output), normalisation of delta-wave EEG architecture, and interaction with opioidergic and GABAergic systems.
Increased slow-wave (delta) sleep duration in EEG studies
Reduced sleep latency and improved sleep continuity
Attenuation of stress-induced cortisol elevation
Reported analgesic activity in chronic-pain research
Possible normalisation of disrupted circadian rhythms
Favourable tolerability with minimal next-day sedation
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Small and often dated human studies sit alongside animal work. A defined receptor target and modern replicated dose–response evidence are still lacking.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 100–300mcg subcutaneously 30–60 minutes before bed, or intranasally. Cycles typically run 4–8 weeks with intermittent use rather than daily long-term administration.
Reported persistence
Plasma half-life is short (approximately 7–20 minutes), but downstream effects on sleep architecture persist well beyond clearance.
Calculator starting point
0.2 mg per reference dose
5 doses per week · 4-week cycle
2 mL default reconstitution volume
100–300 mcg SC pre-sleep, short cycles.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate DSIPLaboratory handling
Reconstitution reference
Reconstitute a 5mg vial with 2–5mL bacteriostatic water for a 1–2.5mg/mL working concentration. Swirl gently.
Storage reference
Lyophilised: 2–8°C, stable 18–24 months; -20°C for long-term storage. Reconstituted: 2–8°C, protect from light, use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Human RCT data is limited and dated; most evidence is mid-20th-century research.
Receptor pharmacology remains poorly characterised — long-term safety profile is not well established.
Mild dizziness or transient headache reported anecdotally at higher doses.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading